| Nov 17 |
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 15 |
Cue Biopharma GAAP EPS of -$0.1, revenue of $3.34M
|
| Nov 14 |
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 14 |
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 14 |
Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role
|
| Nov 14 |
Cue Biopharma Announces Strategic Organizational Transition
|
| Nov 8 |
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
|
| Oct 8 |
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%
|
| Oct 4 |
Cue Biopharma stock rallies nearly 40% on upcoming presentations
|
| Oct 4 |
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
